Inhibition of Brain Epidermal Growth Factor Receptor Activation: A Novel Target in Neurodegenerative Diseases and Brain Injuries

• Published in: Molecular pharmacology Vol. 98; no. 1; pp. 13 - 22
• Main Authors: Tavassoly, Omid, Sato, Takashi, Tavassoly, Iman
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2020
• Subjects: Adult; Animals; Blood-Brain Barrier - drug effects; Brain Injuries - drug therapy; Brain Injuries - metabolism; Central Nervous System - growth & development; Central Nervous System - metabolism; Child; Drug Repositioning; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - metabolism; Gene Expression Regulation, Developmental; Humans; Molecular Targeted Therapy; Neurodegenerative Diseases - drug therapy; Neurodegenerative Diseases - metabolism; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Spinal Cord Injuries - drug therapy; Spinal Cord Injuries - metabolism; Up-Regulation - drug effects; NPC; NDDs; BBB; ALS; CNS; WB; EGFR; PS1; ZNRF1; p-EGFR; PI3K; SNP; mTOR; NSC; AD; IL; NSCLC; OGD; GFAP; GSK3β; TNF-α; CRMP2; CSPG; SCI; HER1

Several reports have been published recently demonstrating a beneficial effect of epidermal growth factor receptor (EGFR) inhibitors in improving pathologic and behavioral conditions in neurodegenerative diseases (NDDs) such as Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS) as well as t...